Literature DB >> 29032275

Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.

Betty K Hamilton1, Lisa Rybicki2, Sally Arai3, Mukta Arora4, Corey S Cutler5, Mary E D Flowers6, Madan Jagasia7, Paul J Martin6, Jeanne Palmer8, Joseph Pidala9, Navneet S Majhail1, Stephanie J Lee6, Nandita Khera10.   

Abstract

Chronic graft-versus host disease (GVHD) is a chronic and disabling complication after hematopoietic cell transplantation (HCT). It is important to understand the association of socioeconomic status (SES) with health outcomes in patients with chronic GVHD because of the impaired physical health and dependence on intensive and prolonged health care utilization needs in these patients. We evaluated the association of SES with survival and quality of life (QOL) in a cohort of 421 patients with chronic GVHD enrolled on the Chronic GVHD Consortium Improving Outcomes Assessment study. Income, education, marital status, and work status were analyzed to determine the associations with patient-reported outcomes at the time of enrollment, nonrelapse mortality (NRM), and overall mortality. Higher income (P = .004), ability to work (P < .001), and having a partner (P = .021) were associated with better mean Lee chronic GVHD symptom scores. Higher income (P = .048), educational level (P = .044), and ability to work (P < .001) also were significantly associated with better QOL and improved activity. In multivariable models, higher income and ability to return to work were both significantly associated with better chronic GVHD Lee symptom scores, but income was not associated with activity level, QOL, or physical/mental functioning. The inability to return to work (hazard ratio, 1.82; P = .019) was associated with worse overall mortality, whereas none of the SES indicators were associated with NRM. Income, race, and education did not have statistically significant associations with survival. In summary, we did not observe an association between SES variables and survival or NRM in patients with chronic GVHD, although we found some association with patient-reported outcomes, such as symptom burden. Higher income status was associated with less severe chronic GVHD symptoms. More research is needed to understand the psychosocial, biological, and environmental factors that mediate this association of SES with major HCT outcomes.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic GVHD; Hematopoietic cell transplantation; Patient-reported outcomes; Socioeconomic status

Mesh:

Year:  2017        PMID: 29032275      PMCID: PMC5767523          DOI: 10.1016/j.bbmt.2017.10.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  31 in total

Review 1.  Nutritional and socio-economic status in the prognosis of childhood acute lymphoblastic leukemia.

Authors:  M B Viana; R A Fernandes; B M de Oliveira; M Murao; C de Andrade Paes; A A Duarte
Journal:  Haematologica       Date:  2001-02       Impact factor: 9.941

2.  Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS).

Authors:  Can-Lan Sun; Liton Francisco; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

3.  Systolic blood pressure, socioeconomic status, and biobehavioral risk factors in a nationally representative US young adult sample.

Authors:  Beverly H Brummett; Michael A Babyak; Ilene C Siegler; Michael Shanahan; Kathleen Mullan Harris; Glen H Elder; Redford B Williams
Journal:  Hypertension       Date:  2011-07-05       Impact factor: 10.190

4.  The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.

Authors:  Joseph Pidala; Jongphil Kim; Claudio Anasetti; Taiga Nishihori; Brian Betts; Teresa Field; Janelle Perkins
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

5.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Authors:  Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.

Authors:  Jennifer M Knight; Karen L Syrjala; Navneet S Majhail; Michael Martens; Jennifer Le-Rademacher; Brent R Logan; Stephanie J Lee; Paul B Jacobsen; William A Wood; Heather S L Jim; John R Wingard; Mary M Horowitz; Muneer H Abidi; Mingwei Fei; Laura Rawls; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-23       Impact factor: 5.742

8.  Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Jennifer M Knight; J Douglas Rizzo; Brent R Logan; Tao Wang; Jesusa M G Arevalo; Jeffrey Ma; Steve W Cole
Journal:  Clin Cancer Res       Date:  2015-08-18       Impact factor: 12.531

9.  Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation.

Authors:  Gregory A Abel; Randy Albelda; Nandita Khera; Theresa Hahn; Diana Y Salas Coronado; Oreofe O Odejide; Kira Bona; Reginald Tucker-Seeley; Robert Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-13       Impact factor: 5.742

10.  Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma.

Authors:  Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

View more
  5 in total

1.  Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada.

Authors:  Sonya Cressman; Donna E Hogge; Mark D Minden; Stephen Couban; Aly Karsan; Raewyn Broady; Emily McPherson; Khalif Halani; Jing Yi Weng; Stuart J Peacock
Journal:  EJHaem       Date:  2020-07-10

2.  Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.

Authors:  Sanghee Hong; Ruta Brazauskas; Kyle M Hebert; Siddhartha Ganguly; Hisham Abdel-Azim; Miguel Angel Diaz; Sara Beattie; Stefan O Ciurea; David Szwajcer; Sherif M Badawy; Alois A Gratwohl; Charles LeMaistre; Mahmoud D S M Aljurf; Richard F Olsson; Neel S Bhatt; Nosha Farhadfar; Jean A Yared; Ayami Yoshimi; Sachiko Seo; Usama Gergis; Amer M Beitinjaneh; Akshay Sharma; Hillard Lazarus; Jason Law; Matthew Ulrickson; Hasan Hashem; Hélène Schoemans; Jan Cerny; David Rizzieri; Bipin N Savani; Rammurti T Kamble; Bronwen E Shaw; Nandita Khera; William A Wood; Shahrukh Hashmi; Theresa Hahn; Stephanie J Lee; J Douglas Rizzo; Navneet S Majhail; Wael Saber
Journal:  Cancer       Date:  2020-10-21       Impact factor: 6.860

Review 3.  Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review.

Authors:  Freya Wenzel; Anne Pralong; Udo Holtick; Christoph Scheid; Marco Herling; Steffen T Simon
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

4.  Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT.

Authors:  Andrzej Frankiewicz; Christophe Peczynski; Sebastian Giebel; Alenca Harrington; Gerard Socié; Dietger Niederwieser; Christoph Scheid; Martin Bornhäuser; Nicolaus Kröger; Ahmet Elmaagacli; Boris Afanasyev; Peter Dreger; Claudia Rössig; Didier Blaise; Christian Kratz; Ibrahim Yakoub-Agha; Bernhard Kremens; Charlotte Marie Niemeyer; Gerald Wulf; Igor Blau; Olaf Penack; Hildegard Greinix; Grzegorz W Basak
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

5.  Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors.

Authors:  Rahul Banerjee; Jean C Yi; Navneet S Majhail; Heather S L Jim; Joseph Uberti; Victoria Whalen; Alison W Loren; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-08       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.